Chim C. Lang spends much of his time researching Internal medicine, Cardiology, Heart failure, Ejection fraction and Endocrinology. The study of Internal medicine is intertwined with the study of Surgery in a number of ways. Within one scientific family, Chim C. Lang focuses on topics pertaining to Left ventricular hypertrophy under Cardiology, and may sometimes address concerns connected to Aortic valve stenosis, Myocardial perfusion imaging and Asymptomatic.
His Heart failure research is multidisciplinary, relying on both Prospective cohort study, Heart disease, Systole and Intensive care medicine. His Ejection fraction study which covers Cardiac output that intersects with Nitrous oxide, Dilated cardiomyopathy and Transplantation. The various areas that Chim C. Lang examines in his Endocrinology study include Methacholine and Kinase, Protein kinase A.
His primary areas of study are Internal medicine, Cardiology, Heart failure, Endocrinology and Ejection fraction. His work carried out in the field of Internal medicine brings together such families of science as Diabetes mellitus and Surgery. Much of his study explores Cardiology relationship to Left ventricular hypertrophy.
In his study, which falls under the umbrella issue of Heart failure, Proportional hazards model is strongly linked to Hazard ratio. His is doing research in Atrial natriuretic peptide, Effective renal plasma flow, Renin–angiotensin system, Vasodilation and Kidney, both of which are found in Endocrinology. Acute coronary syndrome is the focus of his Myocardial infarction research.
His main research concerns Internal medicine, Heart failure, Cardiology, Ejection fraction and Diabetes mellitus. The study incorporates disciplines such as Post-hoc analysis, Randomized controlled trial, Renal function and Confidence interval in addition to Heart failure. His Cardiology research incorporates elements of Pulse wave velocity, Case-control study and Left ventricular hypertrophy.
His research investigates the connection between Case-control study and topics such as Risk factor that intersect with issues in Arterial stiffness. His work focuses on many connections between Ejection fraction and other disciplines, such as Rehabilitation, that overlap with his field of interest in Stroke volume, Intervention mapping and Intervention. Chim C. Lang combines subjects such as Cohort study and Comorbidity with his study of Diabetes mellitus.
His primary scientific interests are in Heart failure, Internal medicine, Cardiology, Ejection fraction and Diabetes mellitus. His research integrates issues of Hyperkalemia, Cohort and Hazard ratio in his study of Heart failure. His studies deal with areas such as Body mass index and Volume overload as well as Hazard ratio.
His Cardiology research includes themes of Renin–angiotensin system, Left ventricular hypertrophy, Mineralocorticoid receptor and Dose. His Ejection fraction research focuses on Atrial fibrillation and how it relates to Electrocardiography, Clinical significance and Natriuretic peptide. His Diabetes mellitus study combines topics in areas such as Furosemide, Cohort study and Comorbidity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.
Salim Yusuf;Steven Hawken;Stephanie Ôunpuu;Leonelo Bautista.
The Lancet (2005)
QT DISPERSION AND SUDDEN UNEXPECTED DEATH IN CHRONIC HEART FAILURE
C.S. Barr;A. Naas;M. Freeman;C.C. Lang.
The Lancet (1994)
Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure
Donna M. Mancini;Stuart D. Katz;Chim C. Lang;John LaManca.
Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial
Awsan Noman;Donald S C Ang;Simon Ogston;Chim C Lang.
The Lancet (2010)
Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease
Craig S. Barr;Chim C. Lang;Jacqueline Hanson;Michael Arnott.
American Journal of Cardiology (1995)
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
John G. F. Cleland;John R. Teerlink;Roxy Senior;Evgeny M. Nifontov.
The Lancet (2011)
Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status
Amy R. Cameron;Vicky L. Morrison;Daniel Levin;Mohapradeep Mohan.
Circulation Research (2016)
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
Eileen O’Meara;Tim Clayton;Margaret B. McEntegart;John J.V. McMurray.
Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence Results From the CHARM Echocardiographic Substudy-CHARMES
Hans Persson;Eva Lonn;Magnus Edner;Lawrence Baruch.
Journal of the American College of Cardiology (2007)
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Iziah E. Sama;Alice Ravera;Alice Ravera;Bernadet T. Santema;Harry van Goor.
European Heart Journal (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: